A differential proteomics study of cerebrospinal fluid from individuals with Niemann‐Pick disease, Type C1
PROTEOMICS · 2023
DOI: 10.1002/pmic.202200378 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, 2023. Verfasst von Wenping Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Neurodegenerative Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Niemann‐Pick, type C1 (NPC1) is a fatal, neurodegenerative disease, which belongs to the family of lysosomal diseases. In NPC1, endo/lysosomal accumulation of unesterified cholesterol and sphingolipids arise from improper intracellular trafficking resulting in multi‐organ dysfunction. With the proximity between the brain and cerebrospinal fluid (CSF), performing differential proteomics provides a means to shed light to changes occurring in the brain. In this study, CSF samples obtained from NPC1 individuals and unaffected controls were used for protein biomarker identification. A subset of these individuals with NPC1 are being treated with miglustat, a glycosphingolipid synthesis inhibitor. Of the 300 identified proteins, 71 proteins were altered in individuals with NPC1 compared to controls including cathepsin D, and members of the complement family. Included are a report of 10 potential markers for monitoring therapeutic treatment. We observed that pro‐neuropeptide Y (NPY) was significantly increased in NPC1 individuals relative to healthy controls; however, individuals treated with miglustat displayed levels comparable to healthy controls. In further investigation, NPY levels in a NPC1 mouse model corroborated our findings. We posit that NPY could be a potential therapeutic target for NPC1 due to its multiple roles in the central nervous system such as attenuating neuroinflammation and reducing excitotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Illinois Chicago, Chicago, Illinois, USA.
- Eunice Kennedy Shriver, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Biomedical Informatics, The Ohio State University Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Wenping Li, Melissa R Pergande, Stephanie M Cologna
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Intramural NIH HHS
- National Niemann-Pick Disease Foundation
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Li, W., Pergande, M. R., Crutchfield, C. A., Searle, B. C., Backlund, P. S., Picache, J. A., Burkert, K., Yanjanin-Farhat, N. M., Blank, P. S., Toth, C. L., Wassif, C. A., Porter, F. D., & Cologna, S. M. (2023). A differential proteomics study of cerebrospinal fluid from individuals with Niemann‐Pick disease, Type C1. PROTEOMICS. https://doi.org/10.1002/pmic.202200378
Vancouver
Li W, Pergande MR, Crutchfield CA, Searle BC, Backlund PS, Picache JA, et al. A differential proteomics study of cerebrospinal fluid from individuals with Niemann‐Pick disease, Type C1. PROTEOMICS. 2023. doi:10.1002/pmic.202200378
BibTeX
@article{Li2023,
author = {Li, Wenping and Pergande, Melissa R and Crutchfield, Christopher A and Searle, Brian C and Backlund, Peter S and Picache, Jaqueline A and Burkert, Kathryn and Yanjanin-Farhat, Nicole M and Blank, Paul S and Toth, Cynthia L and Wassif, Christopher A and Porter, Forbes D and Cologna, Stephanie M},
title = {A differential proteomics study of cerebrospinal fluid from individuals with Niemann‐Pick disease, Type C1},
journal = {PROTEOMICS},
year = {2023},
doi = {10.1002/pmic.202200378}
}
EUVIMED